Last Updated: 01 Jul 2025
Source: Statifacts
「すべてのCookieを受け入れる」をクリックすると、サイトのナビゲーション向上、サイト利用状況の分析、 およびマーケティング活動の支援のために、お使いのデバイスにCookieを保存することに同意したものとみなされます。
プライバシーポリシー
?????????????2024??22?7000??????????2034?????108?5400?????????????????2025???2034????????????CAGR?16.93????????????????????????????????????????????????????????????????? ???????????????????????????????????CAGR??????????????
| ???? | ?? |
| 2025?????? | 25?9200???? |
| 2034???????? | 10,854????? |
| 2025???2034????????? | ???????CAGR?16.93% |
????????????????????????????????????????????????????????????????????????DNA??????????????????????????????????????????????????????????????????????????????????????????????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????AI????????????????????????????????????????????????AI????????????????????????????????????????????????????????????????????????? ???????????????????????????????????????????????????????????????????????????????????????????????AI???????AI???????????????????????????????????????????????????????????????
CRISPR-Cas9?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ??????COVID-19???????????????????????????????????????????????????????????????????????????COVID-19?????????????????????????????????????????mRNA-1273??COVID-19??????94.5%?????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????FDA????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ????CRISPR?AI?????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????1??????????????????????????
????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????
2024???????????????????????????????????????FDA???????????????????????????????????????????????????????????????????????????????????????????????????????CMO??????????????????????? ??????????????????????????????????????2025?6???????????FDA???AAVrh.74??????????RP-A701????????????????FDA????????????????????????????????????????BAG3?????????BAG3-DCM??????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????2024?12?31???????????96?7600?????2023??1.62%??????
???????2024???????517?2200?????2023??????10.85%???????2023????????466?6000?????2022???7.36%???????
???????????2023???????2,950?????????????ZYNTEGLO???SKYSONA?????????
発行元 Rohan Patil
Last Updated: 01 Jul 2025
Source: Statifacts
Last Updated: 01 Jul 2025
Source: Statifacts
| Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene Augmentation | 2,896.10 | 3,331.70 | 3,852.80 | 4,482.10 | 5,250.00 | 6,186.10 | 7,319.90 | 8,697.70 | 10,386.90 | 12,434.90 | 14,855.10 |
| Gene Editing | 1,664.70 | 1,910.70 | 2,204.50 | 2,558.90 | 2,990.70 | 3,516.10 | 4,151.40 | 4,922.00 | 5,865.20 | 7,006.60 | 8,352.40 |
| Oncolytic Viral Therapy | 885.60 | 1,006.60 | 1,150.00 | 1,321.60 | 1,529.30 | 1,780.00 | 2,080.40 | 2,441.60 | 2,879.80 | 3,404.90 | 4,016.90 |
| RNA-Based Therapy | 654.00 | 737.40 | 835.60 | 952.40 | 1,092.70 | 1,260.90 | 1,460.80 | 1,699.00 | 1,985.60 | 2,325.60 | 2,717.20 |
Last Updated: 01 Jul 2025
Source: Statifacts
| サブセグメント | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene Augmentation | 2,896.10 | 3,331.70 | 3,852.80 | 4,482.10 | 5250 | 6,186.10 | 7,319.90 | 8,697.70 | 10,386.90 | 12,434.90 | 14,855.10 |
| Gene Editing | 1,664.70 | 1,910.70 | 2,204.50 | 2,558.90 | 2,990.70 | 3,516.10 | 4,151.40 | 4922 | 5,865.20 | 7,006.60 | 8,352.40 |
| Oncolytic Viral Therapy | 885.60 | 1,006.60 | 1150 | 1,321.60 | 1,529.30 | 1780 | 2,080.40 | 2,441.60 | 2,879.80 | 3,404.90 | 4,016.90 |
| RNA-Based Therapy | 654 | 737.40 | 835.60 | 952.40 | 1,092.70 | 1,260.90 | 1,460.80 | 1699 | 1,985.60 | 2,325.60 | 2,717.20 |
Gene therapy is a broad term for a number of biotechnological and therapeutic approaches that modify or replace faulty genes to treat or prevent disease. It uses vectors, often viruses, to deliver genetic material into a patient�s cells to correct underlying genetic disorders
Gene therapy is being developed for conditions like inherited genetic disorders, certain cancers, and rare diseases such as spinal muscular atrophy, hemophilia, and retinal diseases.
The market is expanding due to advancements in genetic engineering, increasing approvals of gene-based drugs, rising prevalence of rare and chronic diseases, and strong R&D investments.
High treatment costs, complex regulatory approvals, manufacturing scalability, and long-term safety concerns remain key hurdles to widespread adoption.
Who are the leading players in the market? Major players include Novartis, Spark Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical, and Bluebird Bio, all of which are developing and commercializing gene-based treatments globally.
To get full access to our Market Insights, you need a Professional Account or a Business Suite.
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.